Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices
Science8 min read

503A vs 503B Pharmacies & the 28-Day Rule for GLP-1s

What 503A and 503B mean for compounded GLP-1s, why the shortage ending changed the rules, what the 28-day rule is, and how to spot a legitimate operation.

Updated October 8, 2026

Medically reviewed on

How we review

The quick answerA 503A pharmacy compounds for a named patient on a prescription and answers to its state board; a 503B outsourcing facility is FDA-registered and makes larger batches under manufacturing standards. Since semaglutide and tirzepatide left the FDA shortage list, a legitimate compounded GLP-1 comes from a licensed pharmacy filling a patient-specific prescription. The 28-day rule is the standard use period for an opened multi-dose vial - which is why plans ship monthly and a 90-day vial is a warning sign. Ask the pharmacy's name, its state licence, and the beyond-use date.

Key takeaways

  • 503A pharmacies compound for a named patient on a prescription and answer to state pharmacy boards; 503B outsourcing facilities are FDA-registered and inspected, and make larger batches under manufacturing standards.
  • Semaglutide and tirzepatide are no longer on the FDA shortage list, which closed the bulk-compounding exemption; today a legitimate compounded GLP-1 comes from a licensed pharmacy filling a patient-specific prescription.
  • The 28-day rule comes from sterile-compounding standards: an opened multi-dose vial is generally assigned a 28-day use period, which is why plans ship monthly and why a vial sized for far longer is a warning sign.
  • Ask any provider three things: the pharmacy's name and state licence, whether it is 503A or 503B, and the beyond-use date on the vial. In 2026 the FDA sent warning letters to dozens of telehealth companies over marketing claims; the pharmacy question is how you check the product itself.

Why the pharmacy matters more than the website

The short answerA 503A pharmacy compounds for a named patient on a prescription and answers to state pharmacy boards; a 503B outsourcing facility is FDA-registered and inspected and makes larger batches under manufacturing standards. Semaglutide and tirzepatide are no longer on the FDA shortage list, which closed the bulk-compounding exemption, so a legitimate compounded GLP-1 today comes from a licensed pharmacy filling a patient-specific prescription. The 28-day rule comes from sterile-compounding standards: an opened multi-dose vial is generally given a 28-day use period, which is why plans ship monthly.
An online GLP-1 provider is three things wearing one brand: a website, contracted clinicians who review your form, and a partner pharmacy that actually makes and ships the medication. The first two decide whether you get a prescription; the third decides what is in the vial. Experienced buyers learn to ask about the third first, and the vocabulary they use - 503A, 503B, beyond-use date, the 28-day rule - is the subject of this page. None of it requires a chemistry degree; it requires knowing which questions have checkable answers.

For the 2026 enforcement record on both pharmacy types (the September 18, 2026 Empower warning letter under 503A and the April 30, 2026 proposal to keep semaglutide off the 503B bulks list), see is compounded semaglutide going away?

Our top 2 picks

Our two recommended GLP-1 providers, shown with the same verified pricing and ratings as our full comparison.

Our Top Pick
1
embody logo

Exceptional

9.8out of 10

Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery

Free expedited deliveryNo hidden fees
  • Compounded semaglutide ($49/mo) and tirzepatide ($99/mo) as shown on the homepage, Nov 16, 2026; not FDA-approved
  • Online intake, then a prescriber review by OpenLoop Health, a network of US-licensed doctors
  • Free expedited delivery (embody's words); the Terms do not guarantee a delivery timeline
  • No insurance required, no clinic visits; cancel at least 72 hours before the next billing date

from $49/month

Doctor-prescribed compounded GLP-1 treatment, not FDA-approved: semaglutide shown at $49/month and tirzepatide at $99/month on embody's homepage (Nov 16, 2026), no insurance required.

Read full embody review
2
altRx logo

Excellent

9.4out of 10

Most Comprehensive GLP-1 Medication Access

Transparent pricingNo insurance required
  • Compounded GLP-1 from $89/mo, GLP-1 + GIP from $149/mo
  • Brand-name options too: Zepbound and Wegovy
  • Clinician-guided - physician, PA, or nurse practitioner
  • Free shipping (about 5-7 days)

from $89/month

Affordable GLP-1 program from $89/month - compounded semaglutide and tirzepatide plus brand-name options - with clinician-guided, self-pay care and no insurance required.

Read full altRx review

What is a 503A pharmacy?

Section 503A of the federal Food, Drug and Cosmetic Act covers traditional compounding pharmacies: a licensed pharmacist prepares a medication for a specific, named patient on a valid prescription. These pharmacies are licensed and inspected by their state board of pharmacy, must follow the compounding standards published by the United States Pharmacopeia (USP), and cannot make large batches in advance for general sale. When a telehealth provider says its medication comes from "a licensed US 503A pharmacy", this is what it means - and because the prescription is patient-specific, it is the model that fits how these providers work. embody, for example, names US-based 503A pharmacies and LegitScript certification on its page; our 12-point checklist treats the named pharmacy as a core check.

What is a 503B outsourcing facility?

Section 503B, added in 2013, created a second category: outsourcing facilities that register with the FDA, are inspected by the FDA, and must follow current good manufacturing practice - the same quality framework as drug manufacturers. In exchange they can compound larger batches without a prescription for each patient, typically to supply hospitals and clinics.

During the 2022-2024 shortages of semaglutide and tirzepatide, both 503A pharmacies and 503B facilities were permitted to compound them, which is how the market of compounded GLP-1s grew so quickly. Neither category makes an FDA-approved drug: a 503B facility's product is made under manufacturing standards, but it is still a compounded product with no trials of its own.

Shop GLP-1 plans by product

The lowest published plans - cheapest first, conditions under each price.

What changed when the shortages ended?

The FDA removed tirzepatide and then semaglutide from its shortage list between late 2024 and early 2025, and with that the exemption that allowed compounding of "essentially a copy" of a commercially available drug closed. The standard rules apply again: compounding has to be for a specific patient on a valid prescription, with a clinical reason, through a 503A pharmacy - not bulk production of a copy of Wegovy or Zepbound.

The FDA has followed up on the marketing side: warning letters to telehealth companies in 2026 objected to products described as "generic" Ozempic or Wegovy, as containing "the same active ingredient as" the brand drug, or as coming from an "FDA-approved pharmacy" - the FDA approves drugs, not pharmacies. If a provider's page uses that language, it is a signal about the provider, whatever the pharmacy.

The honest framing is in compounded vs brand-name.

What To Know Before Starting GLP-1 Treatment

Before starting GLP-1 treatment, it's important to understand a few key things. These medications require a prescription from a licensed clinician and aren't suitable for everyone. Some people may experience side effects, especially during the first few weeks as the body adjusts.

GLP-1s also tend to work best when combined with basic lifestyle habits like balanced nutrition and regular physical activity.

That's why choosing a provider that offers proper medical screening and ongoing follow-up support is essential for both safety and long-term success.

Woman preparing GLP-1 weight loss injection

What is the 28-day rule?

Compounded GLP-1 injections are usually dispensed as a multi-dose vial you draw from weekly. Sterile-compounding standards assign every such preparation a beyond-use date - the point after which it should not be used - and for an opened multi-dose vial the conventional limit is 28 days from first puncture, which is why experienced buyers talk about "the 28-day rule".

Two practical consequences. First, this is why legitimate plans ship every four weeks: a vial sized for a month matches the rule.

One captured welludr reviewer's complaint title was simply "They charge you every 21 days" - billing cadence and the vial's use period are worth matching up before you sign. Second, a vial sold as a three-month supply to draw from across 90 days is a warning sign, not a bargain.

The beyond-use date should be printed on the label; if it isn't, ask the pharmacy, not the provider.

The questions that separate a legitimate operation

Four, all with checkable answers. Which pharmacy fills my prescription, and in which state is it licensed? A legitimate provider names it; you can verify the licence on that state board's website. Is it 503A or 503B? Either can be legitimate; evasion is the warning sign. What is the beyond-use date on the vial, and how is it shipped? Cold-chain shipping with a dated label is the standard; our provider comparison records what each provider promises. Who decides my dose? "A licensed clinician reviews your history and prescribes" is the right answer; "guaranteed approval" is the wrong one. Providers that pass all four are in our verified ranking, and the ones we have examined most closely are written up in is embody legit and is welludr legit.

What no pharmacy can supply is an unapproved "research peptide" sold without a prescription; that is a different market entirely. This article is general information about how compounding is regulated; a licensed clinician decides whether any treatment is appropriate for you.

Ready to compare weight loss providers?

See how top providers stack up on pricing, medical support, and treatment options.

Medical disclaimer

This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.

Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.

Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)